Dovitinib
As of the edition of 20 October 2026, Dovitinib is a small molecule: in active development; acts on FGFR3, FLT1 and FLT3 and 5 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2025
- Kind
- Small molecule
- Registered trials
- 59, 19 stopped early
- Disease areas
- Cancer; Digestive system; Urinary and reproductive; Hormones; Pregnancy and women's health; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
4 company-target rows on route B and 8 company-target rows on route A because of this drug.
Companies on route B for this drug
In the product4 company-target rows are on route B because of Dovitinib.
See the 4 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Companies on route A for this drug
In the product8 company-target rows are on route A because of Dovitinib.
See the 8 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| PDGFRB | Platelet-derived growth factor receptor beta | P09619 |
| KIT | Mast/stem cell growth factor receptor Kit | P10721 |
| PDGFRA | Platelet-derived growth factor receptor alpha | P16234 |
| FLT1 | Vascular endothelial growth factor receptor 1 | P17948 |
| FGFR3 | Fibroblast growth factor receptor 3 | P22607 |
| FLT4 | Vascular endothelial growth factor receptor 3 | P35916 |
| KDR | Vascular endothelial growth factor receptor 2 | P35968 |
| FLT3 | Receptor-type tyrosine-protein kinase FLT3 | P36888 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 22 | 11 | 0 | 10 |
| Phase 2 | 35 | 23 | 1 | 9 |
| Phase 3 | 2 | 2 | 0 | 0 |
| All trials | 59 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Novartis | Lead sponsor of trials | 2003 to now |
| Henan Genuine Biotech | Lead sponsor of trials | 2022 to now |
| Allarity Therapeutics | Lead sponsor of trials | 2023 to now |